Clinical Trial

Modified Huanglian Wendan Decoction for Metabolic Syndrome

Completed
View on ClinicalTrials.gov →
Summary
This randomized controlled clinical study aims to evaluate the effect of Modified Huanglian Wendan Decoction on oxidative stress in patients with metabolic syndrome. A total of 180 patients with metabolic syndrome from The First Affiliated Hospital of Heilongjiang University of Chinese Medicine will be assigned to a control group or an observation group at a 1:1 ratio. Participants in both groups will receive lifestyle intervention and standard therapy, including antihypertensive, hypoglycemic, and lipid-lowering treatment. Participants in the observation group will additionally receive Modified Huanglian Wendan Decoction for 3 months. The study will compare changes in oxidative stress indicators, obesity-related parameters, blood pressure, glucose and lipid metabolism, and insulin resistance before and after treatment.
Trial Details
NCT Number NCT07702669
Lead Sponsor First Affiliated Hospital of Heilongjiang Chinese Medicine University
Conditions Metabolic Syndrome
Enrollment 180 participants
Start Date 2023-10-01
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14